A neurologist's personal battle against Alzheimer's disease
A few days ago, the proofs of my new book Dispatches from the Land of Alzheimer’s arrived. The book is a collection of my essays about Alzheimer’s disease written over the last several years. Many of...
Lois, my wife and a retired librarian, got me started keeping track of my book reading using the Goodreads website in 2008. It took me a couple of years to get it right, remembering...
Last February I posted an essay on this blog titled “Hearing loss, aphasia and dementia” about my increasing problem with understanding speech. I suspected that my trouble with speech was due to a combination...
The results of the phase 3 clinical trial of the anti-amyloid monoclonal antibody donanemab were released simultaneously today at the Alzheimer’s Association Clinical Conference (AAIC) in Amsterdam and in a paper published in JAMA....
Two important things happened this week. On the Fourth of July, my granddaughter Emily got her first ride in a canoe. She was thrilled. The other important thing that happened this week was the FDA...
Cobe Haskell and Bill Ward are two of my oldest friends. I have known them since fourth grade. In 1964 or possibly 1963, Cobe and I started putting together a rock band. In the beginning, our...
Last March on this blogsite, I described evidence that chronic laxative use can increase the risk of getting dementia. The cause of this increased risk was thought to involve disruption of the gut microbiome, the...
After years of failed trials, two and possibly three anti-amyloid monoclonal antibodies have shown efficacy at removing beta-amyloid from the brain of subjects with mild Alzheimer’s disease. Two of them, lecanemab and donanemab, have...
There are now two anti-amyloid monoclonal antibodies that appear to be effective in slowing the progression of cognitive impairment in people with mild Alzheimer’s disease. The benefit may be small, 27% for lecanemab and...
Yesterday Eli Lilly issued a press release summarizing positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slows cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Donanemab is unique...
Recent Comments